Biosimilar User Fee Forecast: Unchanged Or Lower In FY 2019, US FDA Says
Executive Summary
Absence of any fee increases reflects growing numbers of both approved biosimilars and products under development, as well as agency’s commitment to start spending down some of the carryover balance from prior years’ fee collections.
You may also be interested in...
US Biosimilar Fee Collections Fall Short
A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.
After Biosimilar Fee Collections Fall Short, US FDA Modifies Carryover Spend-Down Plan
A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.
Biosimilars: Rise In US FDA Approvals Means Lower Or Flat User Fees In FY 2020
Fees for applications and approved products will stay the same, while product development levies will fall 36%, the FDA announces. The agency’s biosimilar activities are becoming more reliant on funding from the growing number of products approved and less on those still in development.